[Photo] Busy Researchers at Enzychem Lifesciences in Action

Countries around the world are racing to develop vaccines and treatments to overcome the novel coronavirus disease (COVID-19). The domestic bio venture company, Engicam Life Sciences, has received approval for a new drug substance from the U.S. Food and Drug Administration (FDA) and is conducting Phase 2 clinical trials. Researchers are busily working at the manufacturing and production facilities of Engicam Life Sciences' central research institute in Jecheon, Chungbuk, ahead of the New Year 2021. / Reporter Kang Jinhyung aymsdream@

This content was produced with the assistance of AI translation services.